Fortress Biotech, Inc. (FBIO) Dividend History

Company News

• Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

  Fortress Biotech announced the closing of the sale of its subsidiary Checkpoint Therapeutics to Sun Pharmaceutical Industries Limited. The transaction will generate approximately $28 million for Fortress and a 2.5% royalty on net sales of Checkpoint's FDA-approved drug UNLOXCYT.

  Benzinga

  Featured Companies: CKPT FBIOP
• Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

  Fortress Biotech, an innovative biopharmaceutical company, announced the FDA approval of its drug Emrosi for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway. The company also announced a strategic collaboration with Partex NV to accelerate asset identification and evaluation using Partex's proprietary AI platform.

  GlobeNewswire Inc.

  Featured Companies: FBIOP
• Mustang Bio Announces Closing of $8 Million Public Offering

  Mustang Bio, a clinical-stage biopharmaceutical company, announced the closing of a public offering of common stock and warrants, raising approximately $8 million. The company plans to use the proceeds for working capital and general corporate purposes.

  GlobeNewswire Inc.

  Featured Companies: FBIOP MBIO
• Mustang Bio Announces Pricing of $8 Million Public Offering

  Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of $8 million, which it plans to use for working capital and general corporate purposes.

  Benzinga

  Featured Companies: FBIOP MBIO
• Mustang Bio Announces Pricing of $8 Million Public Offering

  Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of common stock, Series C-1 warrants, and Series C-2 warrants, raising approximately $8 million in gross proceeds.

  GlobeNewswire Inc.

  Featured Companies: FBIOP MBIO